Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693588 | 0.78 | FAAH (0.41) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL22951279 | 0.77 | FAAH (0.40) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL22501848 | 0.77 | ELANE (0.44) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL1864917 | 0.77 | FAAH (0.40) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL22233152 | 0.75 | FAAH (0.39) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL28739878 | 0.75 | ELANE (0.42) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL16630273 | 0.74 | GABRA1 (0.40) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL30879097 | 0.74 | FAAH (0.41) | FAAHELANEBCHEPOLBGPR119 | |
| SCHEMBL359804 | 0.73 | FAAH (0.37) | FAAHELANEBCHEMAPK1MEN1 | |
| SCHEMBL692934 | 0.73 | FAAH (0.40) | FAAHELANEBCHEPOLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756833-A | Synthesis method of 1- (tert-butoxycarbonyl) pyrazole-5-boric acid | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024153225-A1 | NOVEL ALPK1 INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4043460-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2024-06-05 | — | — | EP | disclosed |
| CN-117980307-A | Substituted tricyclic compounds as PARP inhibitors and application thereof | 上海瑛派药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2694510-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20130310405-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| WO-2013154878-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2593451-A2 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012007345-A2 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | PARP1, PARP2, PARP11 | FAAH 2196/4885ELANE 1838/4885BCHE 4111/4885 |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | FAAH 4482/4885ELANE 1800/4885BCHE 4496/4885 |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | FAAH 4482/4885ELANE 1800/4885BCHE 4496/4885 |
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | PIK3CA, PIK3CD, PIK3CB | FAAH 4585/4885ELANE 4365/4885BCHE 4516/4885 |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | FAAH 2876/4885ELANE 1219/4885BCHE 1766/4885 |
| US-20140113901-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | PI4KA, PI4KB, PIK3CD | FAAH 4684/4885ELANE 4425/4885BCHE 3182/4885 |
| US-20130310405-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | PIK3CA, PIK3CD, PIK3CB | FAAH 4714/4885ELANE 4523/4885BCHE 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.